OrbusNeich celebrating 25 years of advancing patient’s quality of life

(Hong Kong, April 24, 2025) – OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, proudly celebrated its momentous 25th anniversary with a gala dinner on April 11, 2025. The event brought together nearly 300 distinguished guests from around the world. The evening was a joyous occasion, marked by reflection on the company’s journey and a commitment to future innovations.

Since its inception, OrbusNeich has been dedicated to enhancing the quality of life for patients worldwide suffering from vascular diseases through pioneering technologies. 25 years ago, Mr. Teddy Chien, the Chairman Emeritus and Founder, envisioned a Chinese medical device company capable of competing with large, well-established multinationals on a global scale. From an initial focus on the Asia Pacific market, OrbusNeich has expanded its global footprint to over 70 countries and regions. Our product offerings have been continuously growing in both the coronary and peripheral domain, including our iconic Sapphire semi-compliant and non-compliant balloons, Scoreflex scoring balloons, and JADE PTA balloons, to our recent ventures into structural heart solutions. The Group’s innovative solutions continue to transform treatment options, reflecting its unwavering commitment to integrity, passion, innovation, and performance.

“As we celebrate this milestone, let us remember that our journey is not just about the products we create but the lives we impact through innovation and dedication,” said Mr. David Chien, Chairman, Executive Director, and Chief Executive Officer of OrbusNeich. “Together, we will continue to push boundaries and strive for excellence in the years to come.”

The night was filled with gratitude as OrbusNeich expressed heartfelt appreciation for the trust and support received from all stakeholders such as business partners, staff members, shareholders and the medical community throughout its 25-year journey.

As OrbusNeich looks ahead, the company remains steadfast in its commitment to delivering cutting-edge solutions in the treatment of vascular diseases, continuously striving to set new standards in patient care and healthcare technology.

Speech of Mr. David Chien, Chairman, Executive Director, and Chief Executive Officer of OrbusNeich

Speech of Mr. Teddy Chien, the Chairman Emeritus and Founder of OrbusNeich

Toasting ceremony: Mr. Teddy Chien, Chairman Emeritus and Founder (R5), Mr. David Chien, Chairman, Executive Director and Chief Executive Officer (R4), Ms. Denise Lau, Executive Director and Chief Operating Officer (L5), Mr. Jason Chen, Executive Director and Chief Financial Officer (R3), Mr. Peter Leung, Non-executive Director (R2), Dr. Zhou Yi, Non-executive Director (L3), George Lau, BBS, MH, JP, Independent Non-executive Directors (L4), Dr. Gloria Tam, Independent Non-executive Director (L1), Mr. Alain Khair, Senior Vice President and Chief Commercial Officer (R1), and Mr. Eric Dong, Vice President of Manufacturing and General Manager of Shenzhen (L2)

－ End －

About OrbusNeich Medical Group Holdings Limited
OrbusNeich is a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, our Group sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. With an in-house R&D team boasting over 20 years of product development expertise, our Group has developed world-leading proprietary technologies.